￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Medical News

What is the efficacy of lorlatinib/lorlatinib for advanced non-small cell lung cancer?

2025-10-19 11:44:20

Check Details
What are the contraindications for lorlatinib/lorlatinib? What are the side effects?

2025-10-19 11:44:20

Check Details
Rybrevant Approved in the U.S. to Treat Lung Cancer with EGFR Exon 20 Insertion Mutations

2025-10-19 11:44:20

Check Details
Refractory lung cancer welcomes Rybrevant, the first targeted therapy, with response rate reaching 40%

2025-10-19 11:44:20

Check Details
Canakinumab can reduce lung cancer mortality by 77%?

2025-10-19 11:44:20

Check Details
Lumakras Approved in the U.S. to Treat KRAS-G12C Mutant Non-Small Cell Lung Cancer

2025-10-19 11:44:20

Check Details
Lumakras treats non-small cell lung cancer and achieves overall survival of 12.5 months!

2025-10-19 11:44:20

Check Details
Lung cancer targeted drug Dacomitinib significantly prolongs survival of advanced lung cancer

2025-10-19 11:44:20

Check Details
Pfizer’s second-generation EGFR-TKI dacomitinib_Conhule

2025-10-19 11:44:20

Check Details
ALK-positive metastatic non-small cell lung cancer (NSCLC) new targeted drug-lorlatinib

2025-10-19 11:44:20

Check Details
ALK target-targeted drug: clinical data of lorlatinib

2025-10-19 11:44:20

Check Details
What is the efficacy of pozitinib? What are the common side effects?

2025-10-19 11:44:20

Check Details
Category
相关知识